Baseline Serum Estradiol and Fracture Reduction During Treatment With Hormone Therapy: The Women’s Health Initiative Randomized Trial

Jane A. Cauley; Andrea Z. LaCroix; John A. Robbins; Joseph Larson; Robert Wallace; Jean Wactawski-Wende; Zhao Chen; Douglas C. Bauer; Steven R. Cummings; Rebecca Jackson

doi:10.1007/s00198-009-0953-7

Back

Baseline Serum Estradiol and Fracture Reduction During Treatment With Hormone Therapy: The Women’s Health Initiative Randomized Trial

Journal article

Open access

Peer reviewed

Baseline Serum Estradiol and Fracture Reduction During Treatment With Hormone Therapy: The Women’s Health Initiative Randomized Trial

Jane A. Cauley, Andrea Z. LaCroix, John A. Robbins, Joseph Larson, Robert Wallace, Jean Wactawski-Wende, Zhao Chen, Douglas C. Bauer, Steven R. Cummings and Rebecca Jackson

Osteoporosis international, Vol.21(1), pp.167-177

05/13/2009

DOI: 10.1007/s00198-009-0953-7

PMCID: PMC2787820

PMID: 19436934

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/2787820View

Open Access

Abstract

Introduction: The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels. Methods: We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years. Results: There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo. Conclusion: The effect of HT on fracture reduction is independent of estradiol and SHBG levels. © 2009 International Osteoporosis Foundation and National Osteoporosis Foundation.

fracture

hormone therapy

sex steroid hormones

Women’s Health Initiative

Details

Title: Subtitle: Baseline Serum Estradiol and Fracture Reduction During Treatment With Hormone Therapy: The Women’s Health Initiative Randomized Trial
Creators: Jane A. Cauley - University of Pittsburgh
Andrea Z. LaCroix - Fred Hutch Cancer Center
John A. Robbins - University of California Davis Medical Center
Joseph Larson - Fred Hutch Cancer Center
Robert Wallace - University of Iowa
Jean Wactawski-Wende - University at Buffalo, State University of New York
Zhao Chen - University of Arizona
Douglas C. Bauer - University of California, San Francisco
Steven R. Cummings - California Pacific Medical Center
Rebecca Jackson - The Ohio State University
Resource Type: Journal article
Publication Details: Osteoporosis international, Vol.21(1), pp.167-177
DOI: 10.1007/s00198-009-0953-7
PMID: 19436934
PMCID: PMC2787820
NLM abbreviation: Osteoporos Int
ISSN: 0937-941X
eISSN: 1433-2965
Language: English
Date published: 05/13/2009
Academic Unit: Epidemiology; Injury Prevention Research Center; Internal Medicine
Record Identifier: 9984364424402771

Metrics

16 Record Views

13 Times Cited - Web of Science